A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Phase 2 Unknown 80 enrolled Shanghai Miracogen Inc.

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 as single agent in EGFR-positive unresectable locally advanced or metastatic biliary tract cancer patients who have progressed during or relapsed after at least one prior standard therapy.

Timeline

Start: 2021-04-28
Primary completion: 2024-10
Completion: 2024-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Becotatug Vedotin	Monoclonal antibody	2 mg/kg	Intravenous

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Summary

Timeline

Drugs

Indications